DK0913156T3 - Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis - Google Patents

Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis

Info

Publication number
DK0913156T3
DK0913156T3 DK98308413T DK98308413T DK0913156T3 DK 0913156 T3 DK0913156 T3 DK 0913156T3 DK 98308413 T DK98308413 T DK 98308413T DK 98308413 T DK98308413 T DK 98308413T DK 0913156 T3 DK0913156 T3 DK 0913156T3
Authority
DK
Denmark
Prior art keywords
treatment
activated protein
sepsis
conditions associated
apc
Prior art date
Application number
DK98308413T
Other languages
Danish (da)
English (en)
Inventor
Brian William Grinnell
Daniel Lawrence Hartman
Sau-Chi Betty Yan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK0913156T3 publication Critical patent/DK0913156T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Surgery (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK98308413T 1997-10-20 1998-10-15 Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis DK0913156T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6254997P 1997-10-20 1997-10-20
US6476597P 1997-11-07 1997-11-07
EP98308413A EP0913156B1 (fr) 1997-10-20 1998-10-15 Utilisation de la protéine C activée pour le traitement des conditions d'hypercoagulation assocciées au sepsis

Publications (1)

Publication Number Publication Date
DK0913156T3 true DK0913156T3 (da) 2005-06-27

Family

ID=26742406

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98308413T DK0913156T3 (da) 1997-10-20 1998-10-15 Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis

Country Status (28)

Country Link
US (7) US6037322A (fr)
EP (2) EP1449537A3 (fr)
JP (2) JP3805981B2 (fr)
KR (1) KR100798174B1 (fr)
CN (1) CN1276726A (fr)
AT (1) ATE292979T1 (fr)
AU (1) AU748417B2 (fr)
BR (1) BR9812965A (fr)
CA (1) CA2306983A1 (fr)
DE (1) DE69829721T2 (fr)
DK (1) DK0913156T3 (fr)
EA (1) EA002496B1 (fr)
ES (1) ES2239382T3 (fr)
HK (1) HK1020529A1 (fr)
HU (2) HUP0001237A3 (fr)
ID (1) ID24901A (fr)
IL (2) IL135712A0 (fr)
MY (1) MY117655A (fr)
NO (1) NO20002005L (fr)
NZ (1) NZ504026A (fr)
PL (1) PL200515B1 (fr)
PT (1) PT913156E (fr)
SI (1) SI0913156T1 (fr)
TR (1) TR200001059T2 (fr)
TW (1) TWI225404B (fr)
UA (1) UA72194C2 (fr)
WO (1) WO1999020293A1 (fr)
ZA (1) ZA989385B (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
BR9809304B1 (pt) 1997-04-28 2011-02-08 formulação liofilizada estável, processo para preparação da mesma, bem como forma de dosagem unitária.
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6921751B1 (en) 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
EP1138692A1 (fr) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments de gonadotrophine chorionique humaine comme immunorégulateurs
US20050227925A1 (en) * 2004-04-08 2005-10-13 Robbert Benner Compositions capable of reducing elevated blood urea concentration
US20040202645A1 (en) * 2003-04-08 2004-10-14 Khan Nisar Ahmed Administration of gene-regulatory peptides
US6844315B2 (en) * 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US20030220258A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US7175679B2 (en) * 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
US8680059B2 (en) 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US20040199099A1 (en) * 1998-07-10 2004-10-07 Matson James R Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease
US6287516B1 (en) 1998-07-10 2001-09-11 Immunocept, L.L.C. Hemofiltration systems, methods, and devices used to treat inflammatory mediator related disease
IL142248A0 (en) 1998-10-22 2002-03-10 Lilly Co Eli Methods for treating sepsis
IL142255A0 (en) * 1998-11-13 2002-03-10 Lilly Co Eli Method of treating heparin-induced thrombocytopenia
AU1723200A (en) * 1998-11-23 2000-06-13 Eli Lilly And Company Method of treating sickle cell disease and thalassemia
US7074402B2 (en) 2000-02-04 2006-07-11 The Scripps Research Institute Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein C (APC)
US7291122B2 (en) * 2000-03-24 2007-11-06 Immunocept, L.L.C. Hemofiltration methods for treatment of diseases in a mammal
US6736972B1 (en) 2000-03-24 2004-05-18 Immunocept, L.L.C. Method and system for providing therapeutic agents with hemofiltration for reducing inflammatory mediator related diseases
US8535258B2 (en) * 2000-03-24 2013-09-17 Immunocept, L.L.C. Hemofiltration methods for treatment of diseases in a mammal
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
EP1267915B1 (fr) * 2000-03-28 2005-06-22 Eli Lilly And Company Proteine c activee pour le traitement de la pancreatite
US20050037430A1 (en) * 2000-03-29 2005-02-17 Biotempt B.V. Methods and uses for protein breakdown products
EP1300418A1 (fr) 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Régulation génétique par des oligopeptides
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US7576174B2 (en) * 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
US6787040B2 (en) * 2000-05-16 2004-09-07 Immunocept, L.L.C. Method and system for colloid exchange therapy
US8597516B2 (en) * 2000-05-16 2013-12-03 Immunocept, L.L.C. Methods and systems for colloid exchange therapy
WO2001089558A2 (fr) * 2000-05-24 2001-11-29 Eli Lilly And Company Preparations et techniques permettant de traiter des hypercoagulations
AU2001290553A1 (en) * 2000-09-18 2002-04-02 Eli Lilly And Company Method for using activated protein c for the treatment of coagulation-associated disorders
WO2002069232A2 (fr) 2001-02-19 2002-09-06 Merck Patent Gmbh Procede d'identification d'epitopes de lymphocytes t et utilisation dans la preparation de molecules a immunogenicite reduite
WO2002085117A1 (fr) * 2001-04-24 2002-10-31 Eisai Co., Ltd. Procedes et compositions de prevention et traitement du choc septique et de l'endotoxemie
WO2002100445A1 (fr) * 2001-06-13 2002-12-19 The University Of Sydney Traitement et composition de cicatrisation des plaies
WO2003007686A2 (fr) * 2001-07-19 2003-01-30 Dmi Biosciences, Inc. Utilisation de chelateurs de cuivre pour inhiber l'inactivation de la proteine c
US20030220259A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of neurological disorders
HUP0501111A2 (en) 2001-10-15 2007-12-28 Chiron Corp Treatment of severe pneumonia by administration of tissue factor pathway inhibitor
US20030224995A1 (en) * 2001-12-21 2003-12-04 Khan Nisar Ahmed Treatment of burns
US20040013661A1 (en) * 2001-12-21 2004-01-22 Gert Wensvoort Stratification
US7501391B2 (en) * 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US20030220260A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Peptide compositions
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US20030220261A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
US7560433B2 (en) * 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
AU2003213146A1 (en) * 2002-03-08 2003-09-22 Eli Lilly And Company Activated protein c formulations
TW200407335A (en) * 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
EP1545690A4 (fr) * 2002-08-13 2006-04-12 Arbios Systems Inc Therapie d'echange de plasma selectif
WO2004056309A2 (fr) 2002-12-05 2004-07-08 Socratech L.L.C. Activite neuroprotectrice de la proteine c activee independante de son activite anticoagulante
EP1598368A4 (fr) * 2003-01-20 2007-07-25 Chugai Pharmaceutical Co Ltd Anticorps de neutralisation anti-pci
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7517529B2 (en) * 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
EP2266606B1 (fr) 2003-05-15 2014-09-10 Genentech, Inc. Méthodes et compositions pour la prévention et traitement du sepsis
EP1651252B1 (fr) * 2003-07-08 2014-11-26 The Scripps Research Institute Variants de proteine c activee avec activite cytoprotectrice normale mais avec activite anticoagulante reduite
US9192657B2 (en) * 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
US20090227669A1 (en) * 2004-01-23 2009-09-10 The University Of Toledo Compositions and Methods for Perioperative Bladder Instillation
AU2005244249A1 (en) * 2004-03-17 2005-11-24 Novartis Vaccines And Diagnostics, Inc. Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (TFPI)
AU2005243161A1 (en) * 2004-05-11 2005-11-24 Heptest Laboratories, Inc. Compositions, kit and one-step method for monitoring compounds having anti-factor Xa and/or anti factor iia activities
EP1773371A4 (fr) * 2004-07-23 2009-12-30 Univ Rochester La proteine c activee inhibe les effets secondaires de l'activateur de plasminogene dans le cerveau
WO2006124770A2 (fr) * 2005-05-13 2006-11-23 The Feinstein Institute For Medical Research Traitement de la sepsie et de l'inflammation avec des antagonistes alpha2a-adrenergique
US8088728B2 (en) * 2005-06-24 2012-01-03 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract
JP4846799B2 (ja) 2005-07-05 2011-12-28 バイオテンプト ベー．フェー． 腫瘍の治療
EP1864692A1 (fr) 2006-06-07 2007-12-12 Biotempt B.V. Utilisation de peptides pour la protection contre les radiolésions
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant
GR1005700B (el) * 2006-09-01 2007-10-22 (40%) ����� �������� Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα
WO2008073603A2 (fr) * 2006-10-31 2008-06-19 The Scripps Research Institute Schéma posologique de protéine c activée et de ses variants présentant une activité anticoagulante réduite
RU2445365C1 (ru) * 2010-11-03 2012-03-20 Общество с ограниченной ответственностью "Инновационный Центр "Новые Технологии и Материалы" (ООО "ИЦ Новтехмат") Штамм гибридных культивируемых клеток mus musculus - продуцент моноклональных антител, специфичных к протеину с человека (варианты)
RU2490722C1 (ru) * 2012-04-24 2013-08-20 Федеральное государственное бюджетное учреждение науки Институт химической биологии и фундаментальной медицины Сибирского отделения Российской академии наук (ИХБФМ СО РАН) Способ восстановления кровотока в регионе тромбированной вены в эксперименте
US20150150954A1 (en) 2012-07-04 2015-06-04 The University Of Sydney Treatment of inflammatory skin disorders
AU2014391082B2 (en) 2014-04-16 2020-04-09 Zz Biotech Llc Treatment of abnormal cutaneous scarring
WO2019238787A1 (fr) 2018-06-15 2019-12-19 Ab Sandvik Materials Technology Bande d'acier inoxydable duplex et procédé pour la production de celle-ci

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US5009889A (en) * 1987-12-31 1991-04-23 Oklahoma Medical Research Foundation Treatment of dysfunctional vascular endothelium using activated protein C
GB8819607D0 (en) * 1988-08-17 1988-09-21 Wellcome Found Novel combination
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5254532A (en) * 1989-06-26 1993-10-19 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Preparation for treating and preventing thromboses and thromboembolic complications, use of such a preparation and a method of producing the same
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
JP3434326B2 (ja) * 1992-08-25 2003-08-04 財団法人化学及血清療法研究所 成人呼吸窮迫症候群（ａｒｄｓ）予防、治療剤
JP2825739B2 (ja) * 1993-09-20 1998-11-18 帝人株式会社 急性肝不全治療剤
JP3802104B2 (ja) * 1995-05-31 2006-07-26 財団法人化学及血清療法研究所 脊髄損傷に伴う神経障害の予防・治療剤
WO1997020043A1 (fr) * 1995-11-30 1997-06-05 Zymogenetics, Inc. Production de proteine c chez des animaux transgeniques
BR9809304B1 (pt) * 1997-04-28 2011-02-08 formulação liofilizada estável, processo para preparação da mesma, bem como forma de dosagem unitária.
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
JP2005097313A (ja) 2005-04-14
US6426071B2 (en) 2002-07-30
HU224901B1 (en) 2006-04-28
JP2001520199A (ja) 2001-10-30
SI0913156T1 (en) 2005-10-31
PL340096A1 (en) 2001-01-15
US6008199A (en) 1999-12-28
WO1999020293A1 (fr) 1999-04-29
EP0913156A1 (fr) 1999-05-06
ES2239382T3 (es) 2005-09-16
TR200001059T2 (tr) 2000-10-23
UA72194C2 (en) 2005-02-15
US6037322A (en) 2000-03-14
IL135712A0 (en) 2001-05-20
HUP0001237A2 (hu) 2000-08-28
DE69829721T2 (de) 2006-02-09
BR9812965A (pt) 2001-03-20
KR20010031217A (ko) 2001-04-16
ZA989385B (en) 2000-04-14
EP1449537A3 (fr) 2005-09-21
MY117655A (en) 2004-07-31
NZ504026A (en) 2002-12-20
US6156734A (en) 2000-12-05
ID24901A (id) 2000-08-31
EA002496B1 (ru) 2002-06-27
AU9804098A (en) 1999-05-10
EA200000445A1 (ru) 2000-10-30
TWI225404B (en) 2004-12-21
US20010036456A1 (en) 2001-11-01
HUP0100025A3 (en) 2003-08-28
NO20002005L (no) 2000-05-16
DE69829721D1 (de) 2005-05-19
IL135712A (en) 2010-12-30
NO20002005D0 (no) 2000-04-17
HUP0001237A3 (en) 2002-01-28
EP0913156B1 (fr) 2005-04-13
US6489296B1 (en) 2002-12-03
PT913156E (pt) 2005-08-31
PL200515B1 (pl) 2009-01-30
ATE292979T1 (de) 2005-04-15
KR100798174B1 (ko) 2008-01-24
US6268344B1 (en) 2001-07-31
JP3805981B2 (ja) 2006-08-09
HUP0100025A2 (hu) 2001-05-28
CN1276726A (zh) 2000-12-13
EP1449537A2 (fr) 2004-08-25
AU748417B2 (en) 2002-06-06
HK1020529A1 (en) 2000-05-12
CA2306983A1 (fr) 1999-04-29
US6268337B1 (en) 2001-07-31

Similar Documents

Publication Publication Date Title
DK0913156T3 (da) Anvendelse af aktiveret protein C til behandling af hyperkoagulationstilstande i forbindelse med sepsis
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
ATE241378T1 (de) Kombinationen von vasopressin und adrenergischen wirkstoffen zur behandlung des plötzlichen herztods
DE69132688D1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
SE9302308L (sv) Proteinberedning
BR9811825A (pt) Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
DK0668077T3 (da) Produkter, som indeholder G-CSF og TNF-bindende protein
GR3015765T3 (en) A novel thrombomodulin-like glycoprotein obtainable from urine.
DE3685853D1 (de) Mittel zur behandlung von knochenkrankheiten.
ATE220912T1 (de) Herstellung von st1435 enthaltenden pharmazeutischen zusammensetzungen zur topischen verwendung
IE890580L (en) Therapeutic agent for the prevention of intraventricular hemorrhage in premature infants
HUP0003256A2 (hu) Pentozán-poliszulfát és sói alkalmazása krónikus progresszív érhegesedéssel járó betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
ID23176A (id) Metoda untuk mengobati gangguan pembuluh darah
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
DE3650368D1 (de) Verwendung von Depogen zur Behandlung von eingeschränktem Blutkreislauf.
WO2001041771A3 (fr) Systeme transdermique contenant de l'acide acetylsalicylique pour le traitement de la migraine
UA7180C2 (uk) Препарат для лікування та профілактики атерогенних дисліпопротеїнемій та синдрому гіперкоагуляції
RU97110054A (ru) Способ лечения синдрома "диабетическая стопа"
HUP9903911A2 (hu) PKC inhibitorok alkalmazása a központi idegrendszer HIV-fertőzéssel kapcsolatos megbetegedéseinek kezelésére szolgáló gyógyászati készítmények előállítására
RU2002133046A (ru) Фармацевтическая композиция, содержащая фактор viia и фактор xiii
TH76071A (th) สารผสมสำหรับการบำบัดรักษาการตกเลือด ที่มีแฟกเตอร์ viia ที่ถูกกระตุ้นในการรวมกันด้วย ไฟบริโนเจน และวิธีการใช้สารนี้
DK563886A (da) Terapeutisk komposition
ATE74767T1 (de) Arzneimittelzusammensetzung zur behandlung des lungenverstopfens.
UA40717A (uk) Спосіб лікування хворих з шлунковою кровотечею